SUmmary Status Subcommittee
The first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with renal cell carcinoma was developed by the Society for Immunotherapy of Cancer (SITC) and published online by the Journal for ImmunoTherapy of Cancer, in 2016.
This consensus statement provides expert evidence-based recommendations for the use of cytokine-based immunotherapies, IL-2 and IFN, and the more recently approved drug, nivolumab, a checkpoint inhibitor. This statement includes recommendations for patient selection, toxicity management, clinical end points, and sequencing or combination of therapies.
Published Nov. 15, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma."
Michael B. Atkins, MD (co-chair)Georgetown-Lombardi Comprehensive Cancer Center
Bill BroKidney Cancer Association
Bernard FabaPatient Perspectives
Robert A. Figlin, MD, FACPCedars-Sinai Medical Center
Thomas Hutson, DO, PharmDCharles A. Sammons Cancer Center/Baylor Medical Center
Richard W. Joseph, MDMayo Clinic
David F. McDermott, MDBeth Israel Deaconess Medical Center/Dana-Farber/Harvard Cancer Center
Allan J. Pantuck, MDUniversity of California, Los Angeles Institute of Urologic Oncology
Virginia Seery, MSN, RN, ANP-BCBeth Israel Deaconess Medical Center/Dana-Farber/Harvard Cancer Center
Christopher G. Wood, MDUniversity of Texas MD Anderson Cancer Center
Brian Rini, MD (co-chair)Cleveland Clinic Taussig Cancer Institute
Ron Bukowski, MDCleveland Clinic Taussig Cancer Institute
Jo FabaPatient Advocate
Hans Hammers, MD, PhDJohns Hopkins Sidney Kimmel Comprehensive Cancer Center
Eric Jonasch, MDUniversity of Texas MD Anderson Cancer Center
Bradley C. Leibovich, MD, FACSMayo Clinic
Tom Olencki, DOThe Ohio State University Medical Center
David I. Quinn, MD, PhD, MBBS, FRACPUniversity of Southern California Norris Comprehensive Cancer Center
Martin Voss, MD – Memorial SloanKettering Cancer Center
Laura S. Wood, RN, MSN, OCN®Cleveland Clinic Taussig Cancer Institute
Key points from SITC's Cancer Immunotherapy Guidelines Renal Cell Carcinoma have been distilled into Pocket Guide. This condensed, easily accessible version of the full Cancer Immunotherapy Guideline is a quick-reference tool available in both digital and print.
Download SITC's Cancer Immunotherapy Guidelines Renal Cell Carcinoma Pocket Guide on any desktop or mobile device free today.*
*Available only through the Guideline Central App.
ORDER Digital/Print Guide
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com